FDA-TRACK is FDA's agency-wide performance management program that monitors, analyzes and reports key performance data and projects for FDA's program offices and cross-cutting initiatives.
Researchers at CDER focus on developing the scientific knowledge, methods, tools, and standards needed to develop and evaluate new drugs. In this effort, CDER also engages the wider research community in collaborative research to address critical gaps in our scientific knowledge that hinder drug development. At public meetings, CDER staff obtain vital information from patients to identify and address unmet medical needs. The new knowledge and capabilities obtained through these efforts, and the opportunities they provide to further drug development, are communicated to sponsors and the wider scientific community through scientific guidances, peer-reviewed publications, and a variety of formal and informal meetings, including scientific workshops and advisory committees.
For a complete list of CDER measures and their relevant FDA-TRACK dashboard, refer to the FDA-TRACK CDER Index.
- The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" or “Archived” may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK. The data presented in the visualizations above can be accessed by clicking on the link labeled "Download Policy and Science Development Dataset" located right below the visualizations.
- Scientific Publications by FDA Staff is intended for retrieving detailed information for individual publications.
- As of 2018, these numbers do not include 'epubs ahead of print' publications to prevent double counting if and when the print version is added to the FDA's publications database.